ReShape Lifesciences's market cap is currently ―. The company's EPS TTM is $-3.729; its P/E ratio is -0.04; ReShape Lifesciences is scheduled to report earnings on May 20, 2024, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 1.98M	$ 2.15M	$ 2.25M	$ 2.29M	$ 3.11M
Gross Profit	$ 1.84M	$ 1.29M	$ 1.19M	$ 1.22M	$ 1.60M
EBIT	$ -1.67M	$ -3.53M	$ -3.49M	$ -2.65M	$ -16.48M
EBITDA	$ -1.66M	$ -3.48M	$ -3.44M	$ -2.60M	$ -16.02M
Net Income Common Stockholders	$ -1.70M	$ -3.53M	$ -3.49M	$ -2.66M	$ -16.61M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 4.46M	$ 1.45M	$ 4.57M	$ 8.98M	$ 3.85M
Total Assets	$ 10.66M	$ 7.83M	$ 11.85M	$ 16.35M	$ 11.14M
Total Debt	$ 262.00K	$ 285.00K	$ 307.00K	$ 86.00K	$ 171.00K
Net Debt	$ -4.20M	$ -1.16M	$ -4.26M	$ -8.90M	$ -3.68M
Total Liabilities	$ 4.00M	$ 4.74M	$ 5.11M	$ 7.60M	$ 7.48M
Stockholders Equity	$ 6.66M	$ 3.08M	$ 6.74M	$ 8.75M	$ 3.66M
Cash Flow	-
Free Cash Flow	$ -2.46M	$ -2.78M	$ -6.67M	$ -5.07M	$ -2.91M
Operating Cash Flow	$ -2.46M	$ -2.78M	$ -6.66M	$ -5.06M	$ -2.83M
Investing Cash Flow	-	-	$ -3.00K	$ -7.00K	$ -79.00K
Financing Cash Flow	$ 5.46M	$ -338.00K	$ 2.25M	$ 10.20M	$ 638.00K

Currency in USD

ReShape Lifesciences Earnings and Revenue History

Income Statement >

ReShape Lifesciences Debt to Assets

Balance Sheet >

ReShape Lifesciences Cash Flow

Cash Flow >

ReShape Lifesciences Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing